Save time and jump to the most important pieces.
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its grant application to the ALS Association has been approved for funding. The grant is awarded as part of the Hoffman ALS Clinical Trial Awards Program and is titled "Modulation of ALS neuroinflammation by nasal anti-CD3 monoclonal Antibody". The Association's grant will fund a 20-patient clinical trial of two doses of Tiziana's novel and patented therapeutic candidate, intrana
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference's partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist. The BIO-Europe conference provides a
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has entered into a securities purchase agreement for the purchase and sale of 5,263,158 common shares at a purchase price of $0.95 per share pursuant to a registered direct offering, resulting in gross proceeds of approximately $5 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about Nove
6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
424B5 - Tiziana Life Sciences Ltd (0001723069) (Filer)
NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company will be held on December 29, 2022. The record date for voting at the Annual General Meeting is set as November 30, 2022. The notice, agenda and associated material have been despatched to shareholders via mail and the notice, agenda and related financial statements in the form of the relevant Form 20-F filing are available on the Company's website at https://ir.tizianalifesciences.com/shareholder-services/annual-ge
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a corporate update, including its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS) such as non-active secondary-progressive Multiple Sclerosis (SPMS), Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana, remarked, "We look forward to leveraging the exciting clinical and preclinical results from our
NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Company's novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment. Date:Wednesday, September 8, 2021 Time:4:15 p.m. Eastern Time Live Call:+1-877-407-9716 (U.S. Toll-Free) or +1-201-493-6779 (International)
TSLANVDAWAYAITLRYQQQAAPLAVGOSMCIAMZNData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment
SC 13G - Tiziana Life Sciences Ltd (0001723069) (Subject)
SC 13D - Tiziana Life Sciences Ltd (0001723069) (Subject)
SC 13G/A - Tiziana Life Sciences plc (0001723069) (Subject)
Zacks Investment Research initiated coverage of Tiziana Life Sciences with a rating of Not Rated and set a new price target of $7.50
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. "We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Founder and Executive Chairman of the Board. " Ivor has an invaluable track record in creating substantial value for biotech and pharma companies with his strategic vision in building in
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigious "Giants of MS" award for his outstanding contributions in the area of multiple sclerosis (MS) research. The award ceremony will take place on May 30, 2024 at the Consortium of Multipl
Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective September 1, 2023. In this role, Dr. Clementi will be responsible for overseeing the company's development strategies and advancing its portfolio of groundbreaking therapeutic candidates. Dr. Clementi brings with